Contact this trialFirst, we need to learn more about you.
Antimetabolite
Pemigatinib for Acute Myeloid Leukemia
Recruiting1 awardPhase 1
Portland, Oregon
This trial is testing a new drug, pemigatinib, to see if it can help treat acute myeloid leukemia (AML). AML is a type of cancer that starts in the bone marrow (the soft tissue inside bones where blood cells are made). Pemigatinib works by inhibiting (blocking) a protein called FGFR (fibroblast growth factor receptor). This protein is involved in the growth of leukemia cells.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.